Clinical Trials · NCT00791479
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 167
- Start date
- Dec 2008
- Locations
- 46 sites, 9 countries
- Primary endpoint
- Change From Baseline in Glycosylated Hemoglobin (HbA1c)